Research Articles Library
Literature Analysis Tools
Advanced Search
Filter by PMID, year, source, DOI and other criteria
Literature Analysis
Analyze research trends and hotspots
Batch Export
Export search results to Excel/PDF
Design and Synthesis of Novel sEH Inhibitors for the Treatment of Inflammatory Bowel Disease
Publication Year: 2025 Source: J Med Chem PMID: 40590615 DOI: 10.1021/acs.jmedchem.5c00854
The treatment of inflammatory bowel disease (IBD) may rely on the comprehensive regulation of immune inflammatory factors to reach a favorable therapeutic effect. In the current study, we discovered a series of sEH inhibitors containing a squaryl sulfonamide scaffold that potently inhibited the primary proinflammatory signaling pathways of NF-kappaB. Especially, …
Enhancing the Predictions of Cytomegalovirus Infection in Severe Ulcerative Colitis Using a Deep Learning Ensemble Model: Development and Validation Study
Publication Year: 2025 Source: JMIR Med Inform PMID: 40590844
BACKGROUND: Cytomegalovirus (CMV) reactivation in patients with severe ulcerative colitis (UC) leads to worse outcomes; yet, early detection remains challenging due to the reliance on time-intensive biopsy procedures. OBJECTIVE: This study explores the use of deep learning to differentiate CMV from severe UC through endoscopic imaging, offering a potential noninvasive …
Spondyloarthritis Research and Treatment Network (SPARTAN) Clinical and Imaging Year in Review 2024
Publication Year: 2025 Source: Curr Rheumatol Rep PMID: 40591037
PURPOSE OF REVIEW: Diagnostic delay remains a critical challenge in axial spondyloarthritis (axSpA). This review highlights key clinical and imaging research from 2024 that addresses this persistent issue, with a focus on the evolving roles of MRI, artificial intelligence (AI), and updated Canadian management recommendations. RECENT FINDINGS: Multiple studies published …
Bowel urgency in ulcerative colitis: effect of baseline urgency and change in urgency in response to mirikizumab
Publication Year: 2025 Source: J Patient Rep Outcomes PMID: 40591171
BACKGROUND: Mirikizumab has demonstrated efficacy in moderately to severely active ulcerative colitis. A 1-2-point change in Urgency Numeric Rating Scale (NRS) score can be meaningful for patients. In these post-hoc analyses, we evaluated the efficacy of mirikizumab compared to placebo by baseline Urgency NRS score groups (0-3, 4-6, and 7-10) …
Health-related quality of life outcomes among vedolizumab-treated patients with inflammatory bowel disease in the UK and Ireland: a 52-week observational study (OCTAVO)
Publication Year: 2025 Source: J Patient Rep Outcomes PMID: 40591206 DOI: 10.1186/s41687-025-00846-9
BACKGROUND: Vedolizumab is a gut-selective, anti-lymphocyte trafficking biologic therapy for inflammatory bowel disease (IBD). Clinical trials have demonstrated the positive impact of vedolizumab on patient quality of life (QoL); however, real-world evidence of its impact is limited. We evaluated vedolizumab impact on QoL of patients with IBD during the first …
20-Year Mortality in a Population-Based Cohort of Patients with Inflammatory Bowel Disease from New Zealand
Publication Year: 2025 Source: Dig Dis Sci PMID: 40591228 DOI: 10.1007/s10620-025-09180-y
INTRODUCTION: Inflammatory bowel disease (IBD) can lead to mortality directly through severe disease or indirectly via increased risk of malignancy or infection. There are few studies of IBD mortality from the Southern Hemisphere, while new treatments have become available. We aimed to measure 20-year mortality from a population-based IBD cohort …
Identification and Confirmation of Shared Etiology and Hub Biomarkers in Nonalcoholic Steatohepatitis and Crohn's Disease
Publication Year: 2025 Source: Dig Dis Sci PMID: 40591229
PURPOSE: Non-alcoholic steatohepatitis (NASH) and Crohn's disease (CD) are interconnected through shared pathophysiological processes. Our goal was to identify the key molecules and pathways involved in their coexistence. METHODS: We conducted a comprehensive quantitative bioinformatic analysis utilizing publicly accessible RNA sequencing datasets from the Gene Expression Omnibus (GEO) database, specifically …
An Acute Onset Sweet Syndrome After First Vedolizumab Dose in Crohn's Disease
Publication Year: 2025 Source: Inflamm Bowel Dis PMID: 40591392
No Abstract
Correction to: Novel mRNA Signature for Anti-TNF-α Therapy Primary Response in Patients With Ulcerative Colitis
Publication Year: 2025 Source: Inflamm Bowel Dis PMID: 40591419
No Abstract
Efficacy and Safety of Upadacitinib in a Case of Pediatric Acute Severe Ulcerative Colitis and Immune Thrombocytopenia
Publication Year: 2025 Source: Inflamm Bowel Dis PMID: 40591439
No Abstract
Need more literature?
The current database contains 98453 research articles. If you need to search for more literature or perform AI analysis, please use our knowledge acquisition module or explore external literature resources.
External Resources: Access comprehensive literature databases worldwide